The addition of CD200 to flow cytometry marker panels addressing the diagnosis of this heterogenous group of B cell neoplasms may be particularly helpful in distinguishing some disease entities, in particular CLL and MCL, whose clinical behavior and prognosis are quite different. The gene discussed is CD200; the disease is mantle cell lymphoma.